Cantor Fitzgerald initiated coverage of Camp4 Therapeutics (CAMP) with an Overweight rating and $7 price target
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAMP:
- CAMP4 Initiates GLP Toxicology Studies for CMP-SYNGAP-01
- Camp4 Therapeutics initiates GLP toxicology studies for CMP-SYNGAP-01
- Promising Prospects for CAMP4 Therapeutics: Buy Rating Affirmed Amid Advancements in CMP-SYNGAP-01 Program and Strong Investor Confidence
- Apple initiated, Hershey upgraded: Wall Street’s top analyst calls
- Camp4 Therapeutics downgraded to Neutral from Overweight at JPMorgan